Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kiniksa Pharmaceuticals International PLC KNSA

Healthcare Biotechnology
Kiniksa Pharmaceuticals International, plc is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its portfolio of immune-modulating assets, ARCALYST, abiprubart and mavrilimumab, is based on strong biologic rationale or... see more

Recent & Breaking News (NDAQ:KNSA)

Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab

GlobeNewswire August 3, 2022

Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

GlobeNewswire August 2, 2022

Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 3, 2022

Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022

GlobeNewswire May 2, 2022

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire February 22, 2022

Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration

GlobeNewswire February 22, 2022

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022

GlobeNewswire February 18, 2022

Kiniksa Provides Corporate Update and Outlines Anticipated 2022 Milestones

GlobeNewswire January 10, 2022

Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2022

Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS

GlobeNewswire December 28, 2021

Kiniksa Pharmaceuticals to Present at Evercore ISI 4th Annual HealthCONx Conference

GlobeNewswire November 23, 2021

Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution

GlobeNewswire November 1, 2021

Kiniksa Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 1, 2021

GlobeNewswire October 29, 2021

Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

GlobeNewswire September 21, 2021

Kiniksa Announces Launch of ARCALYST Named Patient Program

GlobeNewswire August 16, 2021

Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity

GlobeNewswire August 3, 2021

Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 2, 2021

Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021

GlobeNewswire July 20, 2021

Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis

GlobeNewswire June 8, 2021

Kiniksa Outlines Next Steps for the Development of Mavrilimumab

GlobeNewswire June 8, 2021